AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 111 min read$CLOV

Reynoso Jamie L. sold $36K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 7,289 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.91 on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jun 11, 2026, 9:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides transparency on executive share activity but does not introduce new operational, regulatory, or financial information about the company.

02

Market read

A routine, pre-arranged insider sale is disclosed; it may slightly influence sentiment but is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

Traders may over-weight small insider sales; the more relevant signal would be large, non-10b5-1 transactions or changes in guidance/regulatory outcomes.

Relevance 2/10Novelty 2/10Timing: Filed 2026-06-11 (same day as the sale)

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. (DE).

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Jamie L. Reynoso sold 7,289 shares in an open-market transaction on 2026-06-11 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven rather than directional.

Evidence & confidence

The filing is a routine insider sale (10b5-1 pre-arranged) with modest dollar value (~$36K), providing disclosure but not new company fundamentals.

Market effects

Sector

No direct sector read-across; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish information.

Key entities

  • issuer
    CLOVER HEALTH INVESTMENTS, CORP. /DE

    Company whose shares were sold by an officer under a 10b5-1 plan.

  • insider
    Reynoso Jamie L.

    CEO, Medicare Advantage; sold 7,289 shares on 2026-06-11.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that typically reduces interpretive weight of insider sales.

Read at source← All news

Related articles

AUG 7
$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

yahoo.com6 min
AUG 6
$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

insurancebusinessmag.com9 min
AUG 5
$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

SEC EDGAR 8-K6 min
JUL 24
$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.

kavout.com4 min